menu search

Down 30% in a month, is there more pain for chemocentryx stock?

The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat ...

February 1, 2022, 6:00 am

Down 30% in a month, is there more pain for chemocentryx stock?

The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat ...

February 1, 2022, 6:00 am

Down 30% in a month, is there more pain for chemocentryx stock?

The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat ...

February 1, 2022, 6:00 am

Down 57% in a month, is there more pain for tg therapeutics stock?

The stock price of TG Therapeutics (NASDAQ: TGTX), a commercial stage biopharmaceutical company focused on the development of novel treatments for B-c...

January 31, 2022, 5:00 am

Down 57% in a month, is there more pain for tg therapeutics stock?

The stock price of TG Therapeutics (NASDAQ: TGTX), a commercial stage biopharmaceutical company focused on the development of novel treatments for B-c...

January 31, 2022, 5:00 am

Down 57% in a month, is there more pain for tg therapeutics stock?

The stock price of TG Therapeutics (NASDAQ: TGTX), a commercial stage biopharmaceutical company focused on the development of novel treatments for B-c...

January 31, 2022, 5:00 am

Argenx to present at upcoming investor conferences

November 10, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...

November 10, 2021, 1:00 am

Argenx to present at upcoming investor conferences

November 10, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...

November 10, 2021, 1:00 am

Argenx to present at upcoming investor conferences

November 10, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...

November 10, 2021, 1:00 am

Chemocentryx's stock jumps 80% after receiving fda approval for vasculitis drug

Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% in premarket trading on Friday after the company said that it had received approval from the Foo...

October 8, 2021, 8:24 am

Chemocentryx's stock jumps 80% after receiving fda approval for vasculitis drug

Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% in premarket trading on Friday after the company said that it had received approval from the Foo...

October 8, 2021, 8:24 am

Chemocentryx's stock jumps 80% after receiving fda approval for vasculitis drug

Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% in premarket trading on Friday after the company said that it had received approval from the Foo...

October 8, 2021, 8:24 am

Argenx to highlight potential first-in-class fcrn antagonist efgartigimod at upcoming neuromuscular meetings

Breda, the Netherlands – October 8 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop...

October 8, 2021, 1:00 am

Argenx to highlight potential first-in-class fcrn antagonist efgartigimod at upcoming neuromuscular meetings

Breda, the Netherlands – October 8 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop...

October 8, 2021, 1:00 am

Argenx to highlight potential first-in-class fcrn antagonist efgartigimod at upcoming neuromuscular meetings

Breda, the Netherlands – October 8 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop...

October 8, 2021, 1:00 am

Eledon pharmaceuticals announces presentation on at-1501 at the virtual 2021 northeast amyotrophic lateral sclerosis consortium

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical compa...

October 7, 2021, 7:51 am

Eledon pharmaceuticals announces presentation on at-1501 at the virtual 2021 northeast amyotrophic lateral sclerosis consortium

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical compa...

October 7, 2021, 7:51 am

Eledon pharmaceuticals announces presentation on at-1501 at the virtual 2021 northeast amyotrophic lateral sclerosis consortium

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical compa...

October 7, 2021, 7:51 am


Search within

Pages Search Results: